Ultomiris (Ravulizumab)

• Hazardous meningococcal infections have been seen in patients treated with Ravulizumab. The use of this medicine increases a patient’s risk to catch serious meningococcal infections (septicemia/meningitis). Meningococcal disease because of any serogroup may emerge. 
• Immunize patients without a known history of meningococcal vaccination at least 14 days prior to their first Ultomiris dose. If urgent ultomiris 10 mg/ml therapy is needed in an unvaccinated patient, administer meningococcal vaccine(s) as quickly as possible and provide patients with 14 days of antibacterial drug prophylaxis.
• Precisely monitor patients for early signs/symptoms of meningococcal infection and assess patients promptly in case infection is suspected. Inform patients of these signs/symptoms and steps to be considered to seek prompt medical care. Meningococcal infection may quickly become life-threatening or fatal in case not identified and treated early.
• After discontinuing therapy with ultomiris 300 mg/30 ml, closely monitor for signs/symptoms of hemolysis, identified by elevated LDH together with sudden reduction in PNH clone size or hemoglobin, or occurrence of symptoms such as abdominal pain, fatigue, shortness of breath (dyspnea), hemoglobinuria, major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction.
• Use of Ravulizumab injection may result in infusion-related reactions including anaphylaxis and hypersensitivity reactions. These reactions typically do not require interruption of therapy. Interrupt the Ravulizumab infusion and institute apt supportive measures in case signs/symptoms of cardiovascular instability or respiratory compromise appear.

What documents are required to import ULTOMIRIS to India?

ULTOMIRIS (ravulizumab) injection can be imported by patients or government hospitals in the name of the patients only.

The following documentation is required to import the product:

• Valid prescription from a qualified doctor.
• Patients diagnostic reports.
• Patient’s Proof of Identity (issued by the Government of India).

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription from the doctor.
• Import permit, if applicable.

Is ULTOMIRIS available in India?

ULTOMIRIS (ravulizumab injection) is a prescription drug that legally requires a medical prescription to be dispensed.

Urgent Meds helps import medicines on the named patient supply (NPS). We are a facilitator providing support with:

• Availability of ULTOMIRIS in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.).
• Medicine price.
• Finding genuine and reliable sources from Canada, Europe, USA, and Australia.
• Ensuring 100% transparency.

ULTOMIRIS can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.

Urgent Meds can facilitate the supply of ULTOMIRIS (prescription medicines) to all locations in the world and in India after fulfilling the legal requirements (if applicable).

Please contact +1-647-818-4196  or write us at info@urgentmeds.in for ULTOMIRIS price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Urgent Meds is proficient in sourcing ULTOMIRIS (Cancer Treatment Medicines) from around the world and has the capability to supply it. We offer global access to the best available treatment for our customers worldwide.

Urgent Meds is committed to dispensing any valid prescription promptly. All prescriptions are dispensed and verified by registered pharmacists and are dispatched only to the patient’s address from New Delhi, India. Your health and well-being are our top priorities.

What is the Generic Name for the trade name drug Ultomiris®?

Ravulizumab is the generic name for the trade name drug Ultomiris®.

What is the Manufacturer Name of Ultomiris®?

Ultomiris® is manufactured by Alexion Pharmaceuticals, Inc.

Is Ultomiris® approved by the FDA?

Yes, Ultomiris® is approved by the FDA. The date of first approval was December 21, 2018.

What is the dosage and form of Ultomiris® supplied?

Ultomiris® is supplied as an injection in three different dosage strengths:

• 300 mg/30 mL (10 mg/mL) in a single-dose vial.
• 300 mg/3 mL (100 mg/mL) in a single-dose vial.
• 1,100 mg/11 mL (100 mg/mL) in a single-dose vial.

What are the most common side effects due to Ultomiris®?

The most common side effects due to Ultomiris® include:

• In patients with PNH: upper respiratory tract infection, headache.
• In patients with aHUS: diarrhea, upper respiratory tract infection, nausea, hypertension, vomiting, headache, and pyrexia.

How much does Ultomiris® cost in India?

The cost of Ultomiris® in India is reasonable and can vary. To procure this complement inhibitor authentically, you can call or WhatsApp +1-647-818-4196 or send an email to info@urgentmeds.in.

What are the storage conditions of Ultomiris®?

Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze or shake.

Is it safe to buy Ultomiris® online from India?

Yes, you can buy Ultomiris® injection online from India authentically through Urgent Meds if Ultomiris® is not available or has not been approved in your home country.